NCT05089279View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

January 18, 2022

Study Completion Date

April 6, 2022

Conditions
Chronic Heart Failure
Interventions
DRUG

D113

QD, PO

DRUG

CKD-349

QD, PO

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05089279 - Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter